The Filing Desk

Adaptive Biotechnologies

ADPT · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

ADPT · Last close · November 13, 2026
$29.04
Value Adaptive Biotechnologies yourself

Adaptive Biotechnologies' revenue rose 54.8% to $277 million in fiscal 2025. Its operating margin was −20.6%, up from −90.8% a year earlier. Free cash flow was −$49 million. The diluted share count rose 3.1%.

ADAPTIVE BIOTECHNOLOGIES CORPORATION Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076902 Updated
Revenue
$277M
54.8%
Operating margin
−20.6%
70.2 pts
Net income
−$60M
 
Free cash flow
−$49M
 
Return on capital
−37.2%
87.5 pts
Market cap
$5.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Adaptive Biotechnologies does

Adaptive Biotechnologies reads the genetic code of a patient's immune system to find out how the body detects and fights disease. It uses gene-sequencing technology, a growing database and machine learning to build diagnostic tests and drug-discovery tools.

It has two main businesses. The first, minimal residual disease (MRD) testing, uses its clonoSEQ test to find tiny amounts of cancer left in patients with blood cancers. clonoSEQ is sold to doctors as a clinical test and to drug companies as an assay for their clinical trials (called MRD Pharma). Adaptive says it was the first test authorized by the U.S. Food and Drug Administration to detect and monitor MRD in multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

The second, Immune Medicine, uses its ability to sequence and map immune cell receptors at scale to support new diagnostic and drug products. Adaptive reorganized the company around these two businesses in 2024.

Its biggest risks, as it describes them

  • It has lost money since it began and may not reach or keep profitability.
  • Insurers and government programs may not cover or pay enough for its clinical tests.
  • It may not be able to expand clonoSEQ to new uses or turn its immune platform into new products.
  • It relies on a limited number of suppliers, often a single one, for lab equipment and materials.
  • Its research spending on new products and services may not pay off.
From Adaptive Biotechnologies's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Adaptive Biotechnologies lost money in fiscal 2025: a net loss of $60 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments353498346222227
Debt incl. finance leases—125131133131
Net debt (negative means net cash)—−373−216−89−96
Net debt to EBITDA—————
Debt to equity—0.3x0.4x0.7x0.6x
Interest coverage—−47.2x−16.4x−14.0x−4.8x
Current ratio3.5x5.1x4.7x2.9x3.3x
Quick ratio3.4x5.0x4.5x2.8x3.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Adaptive Biotechnologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Adaptive Biotechnologies says to expect

  • Full year 2026: MRD revenueAdaptive Biotechnologies expects full year revenue for the MRD business to be between $276 million and $286 million, updated from the previous range between $268 million and $278 million.
  • Full year 2026: operating expensesWe expect full year total company operating expenses, including cost of revenue, to be approximately $350 million, updated from the previous range between $350 million and $355 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Adaptive Biotechnologies shares on the open market, and 11 insiders sold $121.6 million, $87.4 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 13, 2026Julie RubinsteinPresident and COOSold plan11,466$28.93$331,711Form 4
Nov 12, 2026Julie RubinsteinPresident and COOSold plan11,881$29.40$349,301Form 4
Nov 11, 2026Julie RubinsteinPresident and COOSold plan11,881$30.83$366,291Form 4
Nov 11, 2026Susan BobulskyChief Commercial Officer, MrdSold plan1,875$32.00$60,000Form 4
Sep 16, 2026Francis LoChief People OfficerSold plan115,406$28.06$3.2 millionForm 4
Sep 15, 2026Susan BobulskyChief Commercial Officer, MrdSold plan1,195$27.00$32,265Form 4
Aug 26, 2026Katey Einterz OwenDirectorSold9,615$26.00$249,990Form 4
Aug 18, 2026Chad M RobinsCEO and Chairman, DirectorSold278,676$24.48$6.8 millionForm 4
Aug 18, 2026Robert HershbergDirectorSold30,664$24.40$748,208Form 4
Aug 17, 2026Chad M RobinsCEO and Chairman, DirectorSold321,324$25.08$8.1 millionForm 4
Aug 17, 2026Peter M NeupertDirectorSold124,690$25.15$3.1 millionForm 4
Aug 10, 2026Susan BobulskyChief Commercial Officer, MrdSold plan3,000$25.00$75,000Form 4
The latest 12 of 108 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score1 of 94 of 95 of 9
Rule of 40−106.2%−50.1%37.1%
Altman Z''−3.84−7.02−5.91
Accruals ratio−9.1%−10.7%−2.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailPassPass
F-score1 of 94 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Adaptive Biotechnologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Adaptive BiotechnologiesFY2554.8%−20.6%−17.7%−37.2%—5
VericelFY2516.4%4.0%9.0%———Compare
Ligand PharmaceuticalsFY2560.4%15.3%18.2%4.9%−3.8x5Compare
Iovance BiotherapeuticsFY2560.6%−153.1%−127.6%———Compare
ArvinasFY25−0.3%−45.1%−105.0%——5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue38568598154185170179277
Revenue growth—44.8%52.8%15.7%56.9%20.1%−8.1%5.1%54.8%
Gross profit2336637610512795107206
Research and development32397111614214212210394
Operating income−44−50−78−153−209−200−227−162−57
Net income−43−46−69−146−207−200−225−160−60
Diluted EPS (US$)−3.50−3.67−1.01−1.11−1.48−1.40−1.56−1.08−0.39
Diluted shares (millions)121369131140142144147152
Cash flow
Cash from operations−35−32205−150−193−184−156−95−46
Capital expenditure26111962161143
Free cash flow−37−39194−168−254−200−167−99−49
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation71113254356635452
Balance sheet at fiscal year end
Cash and short-term investments—165577688353498346222227
Debt incl. finance leases—————125131133131
Total assets—3339121,116923857661539513
Total liabilities—30341373319392353337288
Shareholders' equity−225−258571743604464308203219
Margins and ratios
Gross margin59.2%64.7%73.8%77.1%68.1%68.8%55.6%59.7%74.2%
Operating margin−115.7%−89.4%−92.2%−155.3%−135.4%−108.0%−133.3%−90.8%−20.6%
Net margin−111.4%−83.4%−80.7%−148.6%−134.3%−108.0%−132.3%−89.1%−21.5%
Free cash flow margin−97.0%−69.3%228.3%−171.3%−164.9%−108.1%−98.1%−55.2%−17.7%
Rule of 40 (growth + FCF margin)—−24.5%281.1%−155.6%−108.0%−88.0%−106.2%−50.1%37.1%
Return on capital——————−195.2%−124.7%−37.2%
Return on equity——−43.9%−22.2%−30.8%−37.5%−58.3%−62.4%−28.2%
Return on assets——−11.0%−14.4%−20.3%−22.5%−29.7%−26.6%−11.3%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Adaptive Biotechnologies' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Adaptive Biotechnologies.